Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1455720Generated: October 26, 2026

Methyl 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzoate → (-)-Salbutamol

https://huagongshe.com/reaction/1455720

Reaction equation

Participants

RoleNameHCIDCharge
ReactantMethyl 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzoateHCID 11086725—
Reactant(Dimethyl sulfide)trihydroboronHCID 12423031—
ReactantDitoluoyl-l-tartaric acidHCID 129746773—
Reactant(+)-di-toluoyl-D-tartaric acidHCID 129858806—
SolventMethanolHCID 887—
Product(-)-SalbutamolHCID 123600—

Reaction Steps

Several patents report synthetic routes using enantiomeric separation, however, the synthetic routes result in low yields of the enantiomerically pure product. Optically pure levalbuterol was synthesized by the borane-methylsulfide reduction of the enantiomerically pure precursor (Formula 2) as described in U.S. Pat. No. 5,399,765. The reaction dissolved a mixture of enantiomers of methyl 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzoate and a chiral acid selected from (−)-di-toluoyl-L-tartaric acid and (+)-di-toluoyl-D-tartaric acid in methanol, upon cooling one stereoisomer crystallized, which was separated, and recrystallized as a diastereomer from methanol, the diastereomer was separated, treated with base, and upon reduction formed optically active levalbuterol.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS07482489B2
Source datasetuspto-grants-2009_01
ORD IDord-c07eb2839d6b4c14a590a0ea09564163
Source noteuspto-grants-2009_01